

Xiaohua Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5596442/publications.pdf>

Version: 2024-02-01

30
papers

453
citations

759055

12
h-index

752573

20
g-index

33
all docs

33
docs citations

33
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenovirus vector encoding TPPII ignites HBV-specific CTL response by activating autophagy in CD8+ T cell. <i>Journal of Viral Hepatitis</i> , 2022, 29, 178-188.	1.0	3
2	Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. <i>Emerging Microbes and Infections</i> , 2022, 11, 639-647.	3.0	36
3	Incorporation of Urinary Neutrophil Gelatinase-Associated Lipocalin and Computed Tomography Quantification to Predict Acute Kidney Injury and In-Hospital Death in COVID-19 Patients. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 120-130.	1.2	24
4	Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2021, 44, 976-982.	4.3	30
5	Advances in 3D cell culture for liver preclinical studies. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 643-651.	0.9	5
6	The features comparison between patients in the ICU and general wards and between patients with different outcomes: a 2020 COVID-19 study. <i>Annals of Palliative Medicine</i> , 2021, 10, 672-680.	0.5	2
7	Ubiquitinated Hepatitis D Antigen-Loaded Microvesicles Induce a Potent Specific Cellular Immune Response to Inhibit HDV Replication in Vivo. <i>Microbiology Spectrum</i> , 2021, 9, e0102421.	1.2	3
8	Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. <i>BMC Infectious Diseases</i> , 2020, 20, 565.	1.3	12
9	HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1. <i>Cancer Management and Research</i> , 2019, Volume 11, 7065-7076.	0.9	25
10	Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. <i>Journal of Viral Hepatitis</i> , 2019, 26, 738-749.	1.0	20
11	Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1289-1300.	2.0	21
12	Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 889-895.	1.0	30
13	Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway <i>in vivo</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 181-190.	0.9	4
14	Hepatitis D Viremia Among Injection Drug Users in San Francisco. <i>Journal of Infectious Diseases</i> , 2018, 217, 1902-1906.	1.9	24
15	An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells. <i>Cell Cycle</i> , 2018, 17, 1220-1234.	1.3	6
16	Immunization with lentiviral vector-modified dendritic cells encoding ubiquitinated hepatitis B core antigen promotes Th1 differentiation and antiviral immunity by enhancing p38 MAPK and JNK activation in HBV transgenic mice. <i>Molecular Medicine Reports</i> , 2018, 18, 4691-4699.	1.1	4
17	A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. <i>Hepatology</i> , 2017, 66, 1739-1749.	3.6	74
18	Correlation between low tapasin expression and impaired CD8+ T-cell function in patients with chronic hepatitis B. <i>Molecular Medicine Reports</i> , 2016, 14, 3315-3322.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Role of tripeptidyl peptidase II in MHC class I antigen presentation: Biological characteristics, cellular crosstalk and signaling. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1954-1958.	2.5	4
20	Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice. <i>Immunobiology</i> , 2016, 221, 813-821.	0.8	12
21	Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice. <i>Molecular Medicine Reports</i> , 2015, 12, 3591-3598.	1.1	4
22	Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro. <i>Molecular Medicine Reports</i> , 2015, 12, 289-296.	1.1	4
23	Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo. <i>Acta Biochimica Et Biophysica Sinica</i> , 2015, 47, 870-879.	0.9	11
24	Fusion protein of tapasin and hepatitis B core antigen 18-27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice. <i>Molecular Medicine Reports</i> , 2014, 9, 1171-1178.	1.1	5
25	Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. <i>Laboratory Investigation</i> , 2014, 94, 478-490.	1.7	14
26	Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo. <i>International Immunopharmacology</i> , 2014, 23, 1-7.	1.7	5
27	The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes <i>via</i> cytoplasmic transduction peptide. <i>Acta Biochimica Et Biophysica Sinica</i> , 2013, 45, 203-212.	0.9	16
28	FDG PET/CT Showing Erythema Nodosum Associated With Tuberculous Lymphadenitis. <i>Clinical Nuclear Medicine</i> , 2013, 38, 992-993.	0.7	8
29	The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. <i>Vaccine</i> , 2010, 28, 3913-3919.	1.7	30
30	Enhancement of cytotoxic T lymphocyte activity by dendritic cells loaded with Tat-protein transduction domain-fused hepatitis B virus core antigen. <i>Acta Biochimica Et Biophysica Sinica</i> , 2008, 40, 996-1004.	0.9	9